Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 88294

Title: Combining prognostic value of serum carbohydrate antigen 19-9 and tumor size reduction ratio in pancreatic ductal adenocarcinoma

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00068348
Position: Editorial Board
Academic degree: MD, PhD

Professional title: Surgeon

Reviewer's Country/Territory: Greece

Author's Country/Territory: China

Manuscript submission date: 2023-09-19

Reviewer chosen by: Yu-Lu Chen

Reviewer accepted review: 2023-11-11 23:05

Reviewer performed review: 2023-11-15 15:56

Review time: 3 Days and 16 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No creativity or innovation

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The article deals with very interesting prognostic values, the serum CA 19-9 and the tumor size changing pre-and post-neoadjuvant therapy in pancreatic ductal adenocarcinoma. The study is well organized, the numer of patients is satisfactory. My concern is why the authors have chosen to include patients with a bilirubin level of, less than 2 mg/dL, since the obstruction has already bbeen resolved. The statistical analysis is accurate. The results are conclusive with the primary end point.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 88294

Title: Combining prognostic value of serum carbohydrate antigen 19-9 and tumor size reduction ratio in pancreatic ductal adenocarcinoma

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03731036
Position: Peer Reviewer
Academic degree: MD, PhD
Professional title: Assistant Professor
Reviewer's Country/Territory: Japan
Author's Country/Territory: China

Manuscript submission date: 2023-09-19

Reviewer chosen by: Yu-Lu Chen

Reviewer accepted review: 2023-11-26 15:11

Reviewer performed review: 2023-12-01 07:58

Review time: 4 Days and 16 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [Y] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No creativity or innovation

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [ ] Grade B: Minor language polishing [Y] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [Y] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The document titled "Combining Prognostic Value of Serum CA 19-9 and Tumor Size Reduction Ratio in Patients with Pancreatic Ductal Adenocarcinoma Underwent Neoadjuvant Therapy" focuses on a medical research study. It examines the prognostic significance of serum CA 19-9 levels and tumor size changes in patients with Pancreatic Ductal Adenocarcinoma (PDAC) before and after neoadjuvant therapy (NAT). There are several studies similar to the one described in your document, indicating a notable interest in the prognostic value of serum CA19-9 and tumor size changes in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing neoadjuvant therapy (NAT) (1-3). These studies indicate that the investigation of serum CA19-9 levels and tumor size reduction as prognostic factors in PDAC patients undergoing NAT is a well-explored area in medical research. Thus, the current paper has been addressed in prior publications. (1) Al Abbas AI et al. Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma. Ann Surg Oncol. 2020 Jun;27(6):2007-2014 (2) Imaoka et al. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

retrospective cohort study. Pancreatology. 2016 Jul-Aug;16(4):658-64. (3) Aoki et al. (2019): Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. BMC Cancer. 2019 Mar 21;19(1):252. Major revision 1 Completion rate of scheduled NAT could be worth checking. 2 The univariable analyses should be describe before multivariable analyses in the part of Efficacy and Pathologic Response. 3 The differences from other papers should be emphasized in the discussion part. Especially, AUC of CR+TR should be focused for predictive factor after NAT. Because the AUC is moderate predictive value. 4 Deep learning model about the staging of pancreatic cancer should be described in the discussion part. (Cao K et al. Deep Learning for Fully Automated Prediction of Overall Survival in Patients Undergoing Resection for Pancreatic Cancer: A Retrospective Multicenter Study. Ann Surg. 2023 Jul 1;278(1):e68-e79.) Minor revision P13 line15; The period（ “survival.“ ）is wrong ?

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 88294

Title: Combining prognostic value of serum carbohydrate antigen 19-9 and tumor size reduction ratio in pancreatic ductal adenocarcinoma

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03731036
Position: Peer Reviewer
Academic degree: MD, PhD
Professional title: Assistant Professor
Reviewer's Country/Territory: Japan
Author's Country/Territory: China

Manuscript submission date: 2023-09-19

Reviewer chosen by: Cong Lin

Reviewer accepted review: 2023-12-18 07:11

Reviewer performed review: 2023-12-18 10:30

Review time: 3 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

statements	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

In preoperative predicting prognosis of Pancreatic Ductal Adenocarcinoma, the significance of the serum CA 19-9 and the tumor size changing pre-and post-neoadjuvant therapy is demonstrated, although the AUC is moderate predictive value. The manuscript has been much improved and is in a nice condition now. The manuscript is an important contribution and I recommend that it be accepted for publication.